share_log

赛隆药业(002898.SZ):子公司获得化学原料药上市申请批准通知书

Sailong Pharmaceutical Group (002898.SZ): Subsidiary has obtained the approval notice for the application for listing of chemical raw materials.

Gelonghui Finance ·  Sep 25, 2024 11:49

On September 25, GelonHui reported that Sailong Pharmaceutical Group (002898.SZ) announced that its wholly-owned subsidiary Hunan Sailong Pharmaceutical Co., Ltd. recently obtained the 'Notice of Approval for the Application for Listing of Hydrochloride Ivabradine as a Chemical Raw Material Drug' issued by the National Medical Products Administration.

The main indications for hydrochloride ivabradine formulations: used for the treatment of paroxysmal supraventricular tachycardia or non-compensatory sinus tachycardia, intraoperative and postoperative tachycardia and/or hypertension.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment